This study is purposed to evaluate the efficacy and safety of YVOIRE® contour compared with Restylane SubQ™ injected into the anteromedial malar region.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
83
YVOIRE® contour injection into the anteromedial malar region
Restylane SubQ™ injection into the anteromedial malar region
Seoul National University Hospital
Seoul, South Korea
Mid Face Aesthetic Scale (MFAS) score
Mean of MFAS score as assessed by the independent blinded rater
Time frame: 26 weeks after treatment
Mid Face Aesthetic Scale (MFAS) score
Mean of MFAS score as assessed by the independent blinded rater
Time frame: 2, 14, and 52 weeks after treatment
Mid Face Aesthetic Scale (MFAS) score
Changes of MFAS score as assessed by the independent blinded rater
Time frame: 2, 14, 26, and 52 weeks after treatment
Mid Face Aesthetic Scale (MFAS) Responder rate
MFAS Responder (at least a one-point improvement on the MFAS) rate as assessed by the independent blinded rater
Time frame: 2, 14, 26, and 52 weeks after treatment
Global Aesthetic Improvement Scale (GAIS) score
Mean of GAIS score as assessed by subject
Time frame: 2, 14, 26, and 52 weeks after treatment
Global Aesthetic Improvement Scale (GAIS) Responder rate
GAIS Responder (at least a one-point improvement on the GAIS) rate as assessed by subject
Time frame: 2, 14, 26, and 52 weeks after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.